Glycemic control in diabetic patients treated with Sitagliptin in a single tertiary centre
Background Sitagliptin is a DPP-IV inhibitor and has been proven to reduce HbA1c by 0.8% when used as monotherapy and up to 2.1% when used in combination with maximum dose of metformin. Objectives To evaluate the glycemic control in patients treated with sitagliptin either as monotherapy or as...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Malaysian Endocrine and Metabolic Society
2014
|
| Subjects: | |
| Online Access: | http://irep.iium.edu.my/50065/ http://irep.iium.edu.my/50065/ http://irep.iium.edu.my/50065/4/OP-37.pdf |